WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000 - 2003: 4. Country Work

WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000 - 2003
(2000; 81 pages) [French]

Table des matières

	Acknowledgements
	Abbreviations, Acronyms & WHO Regions
	Highlights - WHO Medicines Strategy: 2000 - 2003
	1. The Impact of Essential Drugs
		1.1. Substantial progress has been made
		1.2 Unfinished agenda and new challenges
	2. Strategic Directions
		2.1. WHO strategic directions
		2.2 WHO Medicines Strategy: 2000 - 2003
		2.3 Health technology and pharmaceuticals
	3. Core Functions Improving Health Through Knowledge, Advocacy and Partnership
	4. Country Work - Why and How?
		4.1 Country work in context
		4.2 How WHO works with countries on medicines
		4.3 Types of WHO support
	5. Framework for Action: Objectives and Expected Outcomes for 2000 - 2003
		5.1 Policy: Ensure commitment of all stakeholders to national drug policies, to coordinated implementation, and to monitoring policy impact
		5.2 Access: Ensure equitable availability and affordability of essential drugs, with an emphasis on diseases of poverty
		5.3 Quality and safety: Ensure the quality, safety and efficacy of all medicines by strengthening and putting into practice regulatory and quality assurance standards
		5.4 Rational use: Ensure therapeutically sound and cost-effective use of drugs by health professionals and consumers
	6. Monitoring Progress
		6.1 Monitoring, evaluation and indicators
		6.2 Country progress indicators for the WHO Medicines Strategy
		6.3 Indicator values for the WHO Medicines Strategy
		6.4 Improving the monitoring/evaluation process and tools
	References and Notes

4. Country Work - Why and How?

“We are structuring our work to ensure that WHO speaks with one voice in the area of pharmaceuticals and essential drugs...WHO remains committed to working with countries to develop and implement effective national policies and programmes.”

Director-General Dr Gro Harlem Brundtland, address to Ad Hoc Working Group on the Revised Drugs Strategy, Geneva, 13 October 1998.²⁵